AAPS Connection

American Association of Pharmaceutical Scientists

August 2015

AAPS WORKSHOP ON CRYSTAL CITY

VI: BMV for Biomarkers September 28-29, 2015

Renaissance Baltimore Harborplace Hotel **Baltimore**

With the growing focus on Translational Research and the use of biomarkers to drive drug development and approvals, biomarkers have become a significant area of research within the pharmaceutical industry. However, until the FDA's 2013 draft guidance on Bioanalytical Method Validation included consideration of biomarker assays using LC-MS and LBA, biomarker assays were created, validated and used without standards of performance. This resulted in the FDA receiving data substantiating claims of efficacy and safety that it could not rely on to back those claims. Thus, the extension of the BMV to cover biomarkers was made and subsequently was discussed at Crystal City V (CCV) in 2013. As the first forum for industry-Agency discussion, it was recognized that it was an initial discussion, and more in-depth and extensive discussion around the general issues of biomarker measurements (e.g., endogenous levels) and the specific technology strengths and weaknesses would be needed. Two years after CCV and after growing publications and discussions within the bioanalytical community, the time is right to hold a 2-day workshop to address regulated biomarkers used to support new therapeutic labeling claims. The Workshop will permit a broader and more in-depth discussion on the parts of industry and Agency, as well as international regulators, with specific learnings for each, with an ultimate goal of providing a Workshop Report that will serve as the basis of LC-MS and LBA biomarker assays performance.

Goals and Objectives

Provide a more robust discussion of the issues related to biomarkers that are of concern to the FDA and Industry:

- General challenges with biomarkers—endogenous levels (no 'blank matrix'), for protein markers lack of appropriate reference standards.
- Continue the CCV dialogue on Category 1 vs 2 assays, and comparison of Qualitative Assay, Relative Quantitative Assay, Definitive Quantitative Assay with respect to successful and unsuccessful approaches used for LBA and LC-MS assays.

With the growth of LC-MS for biomarkers, previous concepts proposed in an industry white paper (Lee, et al. (2006) are not appropriate and an appropriate operating construct is needed.

For more information, please visit www.aaps.org/CCVI

AAPS WORKSHOP ON CHALLENGES IN THE ASSESSMENT OF SIMILARITY OR EQUIVALENCE OF (NON) BIOLOGICAL **COMPLEX DRUG PRODUCTS**

September 28-29, 2015

Renaissance Baltimore Harborplace Hotel **Baltimore**

How do you evaluate the comparability/similarity of a generic version (follow on) to an innovator drug product that is a complex mixture of structures and cannot be fully characterized by analytical means, where it is not-known what specific characteristics relate to clinically relevant outcomes, and where the product quality depends on a tightly controlled



2810 AAPS Connection

process of manufacturing? Examples of such complex drugs can be found in the group of biologicals, and the non-biological complex drugs (NBCDs), such as the families of liposomes, glatiramoids, iron-carbohydrate complexes, bumin-cytostatic complexes and emulsions. Often these NBCDs are also members of the family of nanomedicines and upcoming associated nanosimilars provide similar challenges. And how do we evaluate the design space of drug products where no two batches of the drug product are exactly the same, not only quantitatively, but also qualitatively?

Goals and Objectives

- To inform the participants on the differences between small molecule generics and similar/follow on versions of (non) biological complex drugs (the science and the regulatory implications).
- To identify the outstanding challenges in the assessment of complex drug similarity and consequences for interchangeability of products.
- To identify differences and commonalities in the behavior of biologicals and (different) NBCD families.
- To engage the relevant stakeholders in a science based discussion and exchange experiences on this topic between industrial, academic and regulatory scientists.
- To report afterwards in the The AAPS journal on potential ways moving forward in this complex drugs arena and to lay the foundation for a globally aligned regulatory policy.

For more information, please visit www.aaps.org/CDP

UPCOMING AAPS MEETINGS

www.aaps.org/meetings/

September 28-29, 2015

Crystal City VI: AAPS Workshop on BMV for Biomarkers Renaissance Baltimore Harborplace Hotel www.aaps.org/CCVI

September 28-29, 2015

AAPS Workshop on Challenges in the Assessment of Similarity or Equivalence of (Non) Biological Complex Drug Products

Renaissance Baltimore Harborplace Hotel www.aaps.org/CDP

October 24, 2015

CRS/AAPS Joint Workshop on Formulation, Processing, and Testing of Functionally Coated Multiparticulates Orange County Convention Center, Orlando, Fla.



October 24-25, 2015

AAPS Workshop on Specific Population Drug Dosing Recommentations: Shifting from Clinical Studies to Predict and Confirm

Orange County Convention Center, Orlando, Fla. www.aaps.org/Subpopulations

October 25, 2015

AAPS Workshop on Nanotechnology in Personalized Medicine

Orange County Convention Center, Orlando, Fla. www.aaps.org/NPM

October 25-29, 2015

2015 AAPS Annual Meeting and Exposition Orange County Convention Center, Orlando, Fla. www.aaps.org/annualmeeting


AAPS ELEARNING

Professional Development On-Demand

Check out the AAPS webinar archive for instant replays of all of our live events. Topics include:

- Biotherapeutic Development
- Regulatory Sciences
- Professional Development
- Immunogenicity and more!

For more information visit www.aaps.org/replay



AAPS Connection

2107 Wilson Blvd., Suite 700, Arlington, Va. 22201-3042 Ph: +1.703.243.2800

2015 ANNUAL MEETING AND EXPOSITION CAREER FAIR

Mark your calendar now for your job search at our upcoming 2015 AAPS Career Fair held in conjunction with the 2015 AAPS Annual Meeting and Exposition from October 25 to 29 at the Orange County Convention Center in Orlando, Fla.

The Career Fair begins Sunday night October 25 through Tuesday afternoon, October 27.

AAPS Connection 2811

For more information, please visit www.aaps.org/ AMcareerfair/

INVITE A FRIEND TO JOIN AAPS

Do you have a friend or colleague who could gain from AAPS membership?

Have you taken a few minutes to tell them about AAPS member benefits, including dozens of electronic on the AAPS website, online journal articles, meeting discounts, and a diverse group of pharmaceutical scientists to network with?

Share the following information with a friend, and extend a personal invitation to join AAPS.

Here are a few highlights of AAPS membership that I think you could utilize:

- AAPS professional development tools like free webinars, full online journal article access, monthly AAPS Newsmagazine, past meeting ePosters, and more.
- Discounted rates on all AAPS meetings and workshops, eCourses, books, and print journal subscriptions.
- An awards, fellows, and travelships program that provides recognition for your contributions to the pharmaceutical

sciences, as well as monetary support to attend the AAPS National Biotechnology Conference or the AAPS Annual Meeting and Exposition.

• Networking and career resources, through the AAPS Online Career Center, AAPS Sections and Focus Groups, and the electronic member directory, from a global community of more than 10,000 pharmaceutical scientists and those working in allied pharmaceutical disciplines.

To join today, browse to http://www.aaps.org/tojoin/or contact AAPS Member Services at +1-877-998-AAPS or membership@aaps.org for assistance.

SHARE YOUR AAPS CONNECTION MEMBER ISSUE WITH A COLLEAGUE!



August 2015

